drugset
drugset / Trial / NCT04508205

CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes

NCT04508205 ↗

Phase 1 Completed 27 enrolled CAGE Bio Inc. ethica Clinical Research Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Open-label multicenter study using CGB-400 Gel to reduce facial redness, bumps, and blemishes.

Timeline

Start
2018-10-26
Primary completion
2019-04-18
Completion
2019-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject CGB-400 Unknown — Topical

Indications

rosacea